Market Closed -
Nasdaq
04:00:00 2024-05-07 pm EDT
|
5-day change
|
1st Jan Change
|
11.72
USD
|
-0.85%
|
|
+1.30%
|
+8.22%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
10,374
|
22,488
|
16,363
|
13,497
|
12,992
|
13,918
|
-
|
-
|
Enterprise Value (EV)
1 |
22,621
|
47,482
|
38,749
|
13,497
|
30,132
|
27,317
|
25,472
|
23,663
|
P/E ratio
|
670
x
|
-16.9
x
|
-12.9
x
|
6.51
x
|
217
x
|
8.45
x
|
14
x
|
15
x
|
Yield
|
-
|
-
|
3.33%
|
-
|
4.43%
|
4.29%
|
4.46%
|
4.61%
|
Capitalization / Revenue
|
0.9
x
|
1.88
x
|
0.91
x
|
0.83
x
|
0.84
x
|
0.92
x
|
0.93
x
|
0.93
x
|
EV / Revenue
|
1.97
x
|
3.97
x
|
2.17
x
|
0.83
x
|
1.95
x
|
1.8
x
|
1.7
x
|
1.58
x
|
EV / EBITDA
|
6.39
x
|
13
x
|
6.03
x
|
2.34
x
|
5.88
x
|
5.62
x
|
5.44
x
|
5.06
x
|
EV / FCF
|
14,222,612
x
|
48,020,024
x
|
15,138,295
x
|
-
|
12,437,892
x
|
-
|
9,250,813
x
|
-
|
FCF Yield
|
0%
|
0%
|
0%
|
-
|
0%
|
-
|
0%
|
-
|
Price to Book
|
0.87
x
|
0.49
x
|
0.8
x
|
-
|
0.64
x
|
0.67
x
|
0.63
x
|
0.6
x
|
Nbr of stocks (in thousands)
|
516,133
|
1,200,000
|
1,209,393
|
1,212,685
|
1,199,671
|
1,187,569
|
-
|
-
|
Reference price
2 |
20.10
|
18.74
|
13.53
|
11.13
|
10.83
|
11.72
|
11.72
|
11.72
|
Announcement Date
|
2/27/20
|
3/1/21
|
2/28/22
|
2/27/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
11,500
|
11,946
|
17,886
|
16,263
|
15,427
|
15,190
|
14,946
|
14,929
|
EBITDA
1 |
3,540
|
3,654
|
6,426
|
5,777
|
5,124
|
4,865
|
4,678
|
4,673
|
EBIT
1 |
3,264
|
3,376
|
6,046
|
5,475
|
4,724
|
4,543
|
4,480
|
4,499
|
Operating Margin
|
28.38%
|
28.26%
|
33.8%
|
33.67%
|
30.63%
|
29.9%
|
29.98%
|
30.14%
|
Earnings before Tax (EBT)
1 |
154.4
|
-721.2
|
-664.4
|
2,813
|
202.9
|
4,099
|
954.5
|
1,035
|
Net income
1 |
16.8
|
-669.9
|
-1,269
|
2,079
|
54.7
|
1,858
|
931.6
|
925
|
Net margin
|
0.15%
|
-5.61%
|
-7.1%
|
12.78%
|
0.35%
|
12.23%
|
6.23%
|
6.2%
|
EPS
2 |
0.0300
|
-1.110
|
-1.050
|
1.710
|
0.0500
|
1.387
|
0.8388
|
0.7811
|
Free Cash Flow
|
1,590
|
988.8
|
2,560
|
-
|
2,423
|
-
|
2,754
|
-
|
FCF margin
|
13.83%
|
8.28%
|
14.31%
|
-
|
15.7%
|
-
|
18.42%
|
-
|
FCF Conversion (EBITDA)
|
44.93%
|
27.06%
|
39.83%
|
-
|
47.28%
|
-
|
58.86%
|
-
|
FCF Conversion (Net income)
|
9,467.26%
|
-
|
-
|
-
|
4,428.88%
|
-
|
295.57%
|
-
|
Dividend per Share
2 |
-
|
-
|
0.4500
|
-
|
0.4800
|
0.5025
|
0.5228
|
0.5403
|
Announcement Date
|
2/27/20
|
3/1/21
|
2/28/22
|
2/27/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
4,537
|
4,342
|
4,192
|
4,117
|
4,078
|
3,876
|
3,729
|
3,919
|
3,942
|
3,837
|
3,691
|
3,833
|
3,917
|
3,888
|
3,821
|
EBITDA
1 |
1,698
|
1,416
|
1,586
|
1,482
|
1,498
|
1,211
|
1,341
|
1,306
|
1,360
|
1,117
|
1,207
|
1,196
|
1,268
|
1,188
|
-
|
EBIT
1 |
1,609
|
1,314
|
1,551
|
1,425
|
1,415
|
1,085
|
1,254
|
1,226
|
1,257
|
986.6
|
1,104
|
1,133
|
1,191
|
1,114
|
1,131
|
Operating Margin
|
35.48%
|
30.26%
|
37%
|
34.6%
|
34.7%
|
27.99%
|
33.64%
|
31.29%
|
31.89%
|
25.71%
|
29.92%
|
29.57%
|
30.4%
|
28.66%
|
29.6%
|
Earnings before Tax (EBT)
|
-
|
-203.9
|
527.5
|
-
|
-
|
-
|
-
|
-
|
402.2
|
-855
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
311.5
|
-263.8
|
399.2
|
313.9
|
354.3
|
1,011
|
224.7
|
264
|
331.6
|
-765.6
|
122.6
|
143.6
|
188
|
187.6
|
-
|
Net margin
|
6.87%
|
-6.08%
|
9.52%
|
7.62%
|
8.69%
|
26.09%
|
6.03%
|
6.74%
|
8.41%
|
-19.95%
|
3.32%
|
3.75%
|
4.8%
|
4.83%
|
-
|
EPS
2 |
0.2600
|
-0.2200
|
0.3300
|
0.2600
|
0.2900
|
0.8300
|
0.1900
|
0.2200
|
0.2700
|
-0.6400
|
0.1167
|
0.1405
|
0.2291
|
0.3038
|
-
|
Dividend per Share
2 |
0.1100
|
0.1100
|
0.1200
|
0.1200
|
0.1200
|
-
|
0.1200
|
0.1200
|
0.1200
|
0.1200
|
0.1248
|
0.1310
|
0.1310
|
0.1373
|
-
|
Announcement Date
|
11/8/21
|
2/28/22
|
5/9/22
|
8/8/22
|
11/7/22
|
2/27/23
|
5/8/23
|
8/7/23
|
11/7/23
|
2/28/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
12,247
|
24,994
|
22,386
|
-
|
17,140
|
13,398
|
11,554
|
9,745
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
3.46
x
|
6.84
x
|
3.484
x
|
-
|
3.345
x
|
2.754
x
|
2.47
x
|
2.085
x
|
Free Cash Flow
|
1,591
|
989
|
2,560
|
-
|
2,423
|
-
|
2,754
|
-
|
ROE (net income / shareholders' equity)
|
19%
|
13.6%
|
20.6%
|
-
|
17%
|
14.9%
|
15.1%
|
11.1%
|
ROA (Net income/ Total Assets)
|
7.13%
|
5.11%
|
-2.18%
|
-
|
0.11%
|
6.4%
|
1.6%
|
1.8%
|
Assets
1 |
235.6
|
-13,110
|
58,189
|
-
|
48,839
|
29,030
|
58,224
|
51,386
|
Book Value Per Share
2 |
23.00
|
38.20
|
16.90
|
-
|
17.00
|
17.60
|
18.50
|
19.50
|
Cash Flow per Share
2 |
3.490
|
2.050
|
2.500
|
-
|
2.320
|
2.320
|
2.290
|
-
|
Capex
1 |
213
|
243
|
457
|
-
|
377
|
436
|
436
|
452
|
Capex / Sales
|
1.85%
|
2.03%
|
2.56%
|
-
|
2.44%
|
2.87%
|
2.92%
|
3.03%
|
Announcement Date
|
2/27/20
|
3/1/21
|
2/28/22
|
2/27/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
11.72
USD Average target price
12.46
USD Spread / Average Target +6.29% Consensus |
1st Jan change
|
Capi.
|
---|
| +8.22% | 13.92B | | +33.43% | 700B | | +26.43% | 569B | | -5.12% | 358B | | +19.59% | 330B | | +4.89% | 287B | | +14.32% | 236B | | +5.79% | 202B | | -9.49% | 197B | | +4.26% | 161B |
Other Pharmaceuticals
|